Breakthrough in Cancer Immunotherapy: Antigen Express Presents Novel Vaccine Approach

Strategic Insights -

Researchers at Antigen Express, a subsidiary of Generex Biotechnology Corp., have made significant advancements in cancer immunotherapy with the development of novel peptide vaccines. At the 12th International Congress of Immunology and the 4th annual conference of FOCIS in Montreal, Quebec, Cathy Blackwell presented a research abstract titled "Enhanced T Helper Cell Epitope Peptide Vaccines for Melanoma." The presentation highlighted the company's work in creating enhanced T helper cell epitope peptide vaccines, which have shown promising results in mouse models for melanoma.

Key Takeaways:

  • Antigen Express scientists have developed a method to enhance peptide presentation to T helper cells by creating hybrid peptides that link the peptide to an immunoregulatory segment of the Ii-protein (the Ii-key peptide).
  • These Ii-key peptide linked-epitope peptide hybrids are presented 200 times more effectively than the epitope-only peptide in vitro.
  • Immunizing mice with Ii-key/melanoma hybrids has resulted in 4-6 fold enhancement of Th1 cells compared to HIV epitopes alone.
  • The enhancement of T helper activation probably augments cytotoxic T lymphocyte activity by stimulating dendritic cells.
  • Antigen Express scientists have also found that Ii-key hybrids containing melanoma epitopes are effective in enhancing T helper cell activation.
  • The company is pursuing programs for the use of these vaccines for HIV, SARS, and smallpox.
  • Antigen Express has received 9 grants from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the Department of Defense for the development of these compounds.

Statistics:

  • 200 times more effective presentation of peptides to T helper cells in vitro.
  • 4-6 fold enhancement of Th1 cells in mice immunized with Ii-key/melanoma hybrids.
  • 9 grants received by Antigen Express for the development of these compounds.
  • 12th International Congress of Immunology and 4th annual conference of FOCIS in Montreal, Quebec.

Sources:

  • Generex Biotechnology Corp. press release, August 23, 2004.
  • NewsRx.com & NewsRx.net.